VoxNeuro has received Health Canada Class II Medical Device designation for its proprietary Cognitive Health Assessment Management Platform™ (CHAMP). VoxNeuro will begin rolling out the software as a medical device across its Canadian Test Centers. This news comes hot on the heels of VoxNeuro’s FDA registration for the distribution of CHAMP as a Class II Exempt Medical Device in the US market this past May.
VoxNeuro’s industry leading neurotechnology is elevating the evaluation of cognitive function. The CHAMP software works in tandem with VoxNeuro’s Cognitive Health Assessment™, a proprietary electroencephalography protocol. By analyzing electroencephalographic event-related potential (ERP) data gathered during the assessment, CHAMP provides rapid, objective and actionable scores of four key cognitive functions: memory, information processing, attention & concentration.
Healthcare providers can use VoxNeuro’s cognitive scores to track cognitive health throughout aging, and to evaluate cognitive function when a brain disorder or symptoms related to cognitive dysfunction such as fatigue, memory loss or brain fog are suspected. Common types of brain disorders that can impact cognitive function include concussion, traumatic brain injury and dementia.
Read the full Financial Post article here